Y-mAbs Therapeutics, Inc. - Common Stock, $0.0001 par value per share (YMAB)

100 filings reported holding YMAB - Y-mAbs Therapeutics, Inc. - Common Stock, $0.0001 par value per share as of Q2 2022.
Y-mAbs Therapeutics, Inc. - Common Stock, $0.0001 par value per share (YMAB) has 90 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC). These institutions hold a total of 24,763,276 shares of 45,101,565 outstanding shares and own 54.91% of the company stock.
Largest 10 shareholders include BlackRock Inc. (2,976,221 shares), Polar Capital Holdings Plc (2,952,671 shares), ALLIANCEBERNSTEIN L.P. (2,815,865 shares), Sofinnova Investments, Inc. (2,194,278 shares), FMR LLC (1,970,844 shares), VANGUARD GROUP INC (1,929,916 shares), WELLINGTON MANAGEMENT GROUP LLP (1,870,379 shares), STATE STREET CORP (1,743,142 shares), GEODE CAPITAL MANAGEMENT, LLC (626,168 shares), and BIOIMPACT CAPITAL LLC (443,702 shares).
This table shows the top 90 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.

* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.